Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
for Chronic Obstructive Pulmonary Disease
Drug: Lunsekimig
54 locations incl. Birmingham
Sponsor: Sanofi
Sex: All·Age: 40 - 80
Code: NCT07190222·Phase 3·Recruiting